Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited)

v3.25.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Shares
Redeemable Convertible
Common Stock
Additional paid in capital
Accumulated deficit
Total
Balance at Dec. 31, 2023 $ 3 $ 166,048 $ (162,970) $ 3,081
Balance (in Shares) at Dec. 31, 2023 4,723,380      
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost [1] $ 12,561 $ 1 3,227 3,228
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (in Shares) [1] 40,470 916,497      
Exercise of Pre-Funded Warrants into shares of Common Stock [1] [2] 5 5
Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares) [1]   477,827      
Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs [1] [2] 19 19
Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (in Shares) [1]   7,518      
Stock-based compensation expenses   909 909
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs [1] $ 19,859 541   541
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (in Shares) 216,417 [1]      
Net loss     (17,327) (17,327)
Balance at Mar. 31, 2024 $ 32,420 $ 4 170,749 (180,297) (9,544)
Balance (in Shares) at Mar. 31, 2024 256,887 6,125,222      
Balance at Dec. 31, 2023 $ 3 166,048 (162,970) 3,081
Balance (in Shares) at Dec. 31, 2023 4,723,380      
Balance at Dec. 31, 2024 $ 18,645 $ 6 186,194 (180,697) 24,148
Balance (in Shares) at Dec. 31, 2024 147,735 18,176,661      
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs [1]   [2] 878   878
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (in Shares) [1]   2,828,283      
Issuance of Common Stock under Inducement Letter Agreements [1]   $ 1 6,472   $ 6,473
Issuance of Common Stock under Inducement Letter Agreements (in Shares) [1]   3,961,109      
Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares)        
Stock-based compensation expenses     659   $ 659
Net loss   (7,659) (7,659)
Balance at Mar. 31, 2025 $ 18,645 $ 7 $ 194,203 $ (188,356) $ 24,499
Balance (in Shares) at Mar. 31, 2025 147,735 24,966,053      
[1] See Note 9A.
[2] Less than $1.